An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 2423 (Primary)
- Indications Neuropathic pain
- Focus Pharmacokinetics
- 07 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 07 Feb 2011 Status changed from recruiting to completedas reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.